StockData

Can-Fite BioPharma vs Inovio Pharmaceuticals

CANF and INO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CANF and INO compare

Can-Fite BioPharma grew revenue faster over the last twelve months (−39.9% versus −100% for Inovio Pharmaceuticals).

Inovio Pharmaceuticals scores higher on the StockData Score (4 against 1 for Can-Fite BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCANFINO
Size and price
Market cap–$169M
Share price$1.53$1.63
Change, 1 year−79.3%−20.5%
Change, 5 years−99.4%−98.1%
Beta (5Y)1.47−0.26
Employees527
StockData Score
Total score14 (better)
Valuation score00
Growth score00
Performance score00
Health score14 (better)
Dividend score00
Valuation
P/B–38.6×
FCF yield–−47.9%
Growth
Revenue growth (TTM)−39.9% (better)−100%
Revenue growth, 5Y average−11.9% (better)−61.2%
Profitability
Operating margin−2457%–
Net margin−2427%–
FCF margin−2210%–
Return on equity−217% (better)−410%
Financial health
Debt / equity–0.00
Interest coverage−35.0×–
Current ratio3.60 (better)1.00
Altman Z-score–−55.23
Piotroski F-score2 (better)1
Dividends and buybacks
Buyback yield–−22.6%
Shareholder yield–−22.6%
Ownership
Held by institutions1.9%31.7%
Held by insiders0.00%0.38%
Short interest, % of float–21.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.